

1 **Human embryos from overweight and obese women display phenotypic and**
2 **metabolic abnormalities**

3 *Running title – Developmental disruption in embryos from overweight women*

4 Authors; Christine Leary^{1,2}, Henry J Leese¹, Roger G Sturme^{1,*}

5 Affiliations; ¹ Centre for Cardiovascular and Metabolic Research, Hull York Medical
6 School, University of Hull, Cottingham Road, Hull, HU6 7RX, UK.

7 ² The Hull IVF Unit, The Women and Children's Hospital, Hull Royal Infirmary, Anlaby
8 Road, Hull, HU3 2JZ, UK

9 * roger.sturme@hyms.ac.uk

10

11 Key words: Obesity, Human Embryo Metabolism, Endogenous Triglyceride,
12 Precocious Development

13

14 **Abstract;**

15 **Study question:** Is the developmental timing and metabolic regulation disrupted in
16 embryos from overweight and obese women?

17 **Summary answer:** Human oocytes from women presenting for fertility treatment
18 with a body mass index (BMI) exceeding 25kg/m² are smaller than those from
19 women of healthy weight, yet post fertilization they reach the morula stage faster.
20 Moreover, the blastocysts from overweight women show reduced glucose
21 consumption and contain elevated levels of endogenous triglyceride.

22 **What is known already:** Female overweight and obesity (OW/OB) is associated
23 with infertility. Moreover, being overweight or obese around conception may have
24 significant consequences for the unborn child, since there are widely acknowledged
25 links between events occurring during early development and the incidence of a
26 number of adult disorders.

27 **Study design, size, duration:** We have performed a retrospective, observational
28 analysis of oocyte size and the subsequent developmental kinetics of 218 oocytes
29 from 29 consecutive women attending for ICSI treatment and related time to reach
30 key developmental stages to maternal bodyweight. In addition we have measured
31 non-invasively the metabolic activity of 150 IVF/ ICSI embryos from a further 29
32 consecutive women who donated their surplus embryos to research, and related the
33 data retrospectively to their BMI.

34 **Participants/materials, setting, methods:** In a clinical IVF setting, we compared
35 oocyte morphology and developmental kinetics of supernumerary embryos collected
36 from overweight and obese women, with a body mass index (BMI) in excess of
37 25kg/m² to those from women of healthy weight. Full informed consent was obtained.
38 A Primovision Time Lapse system was used to measure developmental kinetics and

the non-invasive CONsumption/RElease (CORE) of glucose, pyruvate, amino acids, and lactate were measured on spent droplets of culture medium. Total triglyceride within individual embryos was also determined.

Main results and the role of chance: Human oocytes from overweight women are smaller ($R^2 = -0.45$; $p = 0.001$) and less likely to complete development post-fertilization ($p < 0.001$). Those embryos that do develop reach the morula stage faster than embryos from women of a BMI $< 25 \text{ kg/m}^2$ ($p < 0.001$) and the resulting blastocyst contain fewer cells; notably in the trophectoderm ($p = 0.01$). The resulting blastocysts have reduced glucose consumption ($R^2 = -0.61$; $p = 0.001$), modified amino acid metabolism and increased levels of endogenous triglyceride ($t = 4.11$, $p < 0.001$). Our data further indicate that these differences are independent of male BMI.

Limitations, reasons for caution: Although statistical power has been achieved, this is a retrospective study and relatively small due to the scarcity of human embryos available for research. Consequently, sub analysis of overweight and obese was not possible based on the sample size. The analysis has been performed on supernumerary embryos, originating from a single IVF unit and not selected for use in treatment. Thus it was not possible to speculate how representative the findings would be of the better quality embryos transferred or frozen for each patient.

Wider implications of the findings: The data indicate that the BMI of women at conception is associated with distinct phenotypic changes in the embryo during the preimplantation period highlighting the importance of pre-pregnancy body weight in optimizing the chances of fertility and safeguarding maternal and offspring health. These changes to the metabolic fingerprint of human embryos are most likely a legacy of the ovarian conditions under which the oocyte has matured, may reduce the chances of conception for overweight women and provide good evidence that the metabolic profile of the early embryo is set by sub-optimal conditions around the time

65 of conception. The observed changes could indicate long-term implications for the
66 health of the offspring of overweight and obese women

67 **Study funding/competing interest(s):** Funded by the Hull IVF Unit Charitable Trust
68 and the Hull York Medical School.

69 **Trial registration number: Not applicable.**

70

71 **Introduction**

72 Rates of overweight and obesity are rising in women of reproductive age, in line with
73 the global obesity epidemic. Overweight and obesity, defined as a body mass index
74 within the ranges 25-29.9kg/m² and >30kg/m² respectively, are reported to have a
75 negative impact on female reproductive health, in terms of reduced conception rates,
76 increased rate of miscarriage (Boots and Stephenson, 2011), and maternal, fetal and
77 neonatal complications (Balen, et al., 2007). In addition, being overweight during
78 pregnancy increases the risk of developing gestational diabetes and large for
79 gestational weight infants (Lawlor, et al., 2012); observations of particular importance
80 given that weight at birth correlates with weight in later life (Rogers, et al., 2006).
81 Epidemiological studies indicate that maternal body weight at conception and weight
82 gain during the course of the pregnancy are associated with increased risk of
83 cardiovascular and metabolic diseases in the offspring in later life (Lawlor, et al.,
84 2012, Reynolds, et al., 2013). While it is widely accepted that many adult disorders
85 have their origins in early development (Gluckman and Hanson, 2004) it is
86 increasingly apparent that maternal nutrition in the periconceptual period can affect
87 oocyte quality (Machtinger, et al., 2012), embryo development and offspring health
88 (Connor, et al., 2012).

89

90 The ovarian follicle provides nutrients for the developing oocyte. For example,
91 glucose present in the follicular cavity is principally converted to pyruvate by the
92 granulosa-derived cumulus cells that surround the oocyte which is then transported
93 into the oocyte where it is oxidised to provide ATP (Leese and Barton, 1984). In
94 addition, mammalian oocytes contain a significant endogenous triglyceride
95 repository, (Sturmey, et al., 2009) which provides a source of metabolic energy

during oocyte maturation (Dunning, et al., 2010, Ferguson and Leese, 2006, Sturmey and Leese, 2003).

The ovarian follicular environment is modified in obese women (Valckx, et al., 2012), with elevated levels of triglycerides, glucose and insulin (Robker, et al., 2009) the supply of which to the oocyte can have phenotypic consequences. For example, the exposure of bovine oocytes to a high-fat environment during final maturation reduces embryo viability post fertilisation, changes the expression of key metabolic genes and modifies metabolic activity in the resulting blastocysts (Van Hoeck, et al., 2011). While the pattern of metabolism in human oocytes and preimplantation embryos has been studied in some detail (Brison, et al., 2004, Butcher, et al., 1998, Gardner, et al., 2011, Gott, et al., 1990, Hardy, et al., 1989, Houghton, et al., 2002, Martin, et al., 1993, Sturmey, et al., 2009) little is known about whether the metabolic phenotype of the early embryo is sensitive to maternal body weight at the time of conception. This may be important, since the metabolic profile of preimplantation embryos is linked to ongoing viability (Brison, et al., 2004, Gardner, et al., 2011). Moreover, since critical epigenetic events occur during oogenesis (Kono, et al., 1996) and are completed postnatally (Lucifero, et al., 2004), a sub-optimal periconceptual environment may plausibly have a short- and/or long-term impact on development and set the early embryo on a metabolic trajectory that persists beyond the preimplantation period. This may increase the susceptibility of the offspring to the development of non-communicable diseases, including cancer, (Walker and Ho, 2012) cardiovascular disease and diabetes, the aetiology of which are considered to have a developmental component (Hanson and Gluckman, 2011).

121 The aim of this study was therefore to discover whether embryos derived from
122 oocytes of overweight and obese women display a compromised developmental and
123 metabolic profile. In order to carry out this work, we were fortunate to receive human
124 embryos conceived by In Vitro Fertilisation and donated for research purposes after
125 clinical treatment had been completed, with full, informed ethical consent.

Methods;

All research was carried out according to licence conditions of the Human Fertilisation and Embryology Authority (licence R0067), with full ethical approval (09/HI304/44).

Female and male BMI were recorded at the down-regulation appointment and at the commencement of treatment to ensure that the patients were weight-stable (defined as maintaining weight over a period of three months). Embryos that originated from patients classified as OW/OB ($\text{BMI} \geq 25\text{kg/m}^2$) were compared to embryos derived from women of normal BMI (19 to 24.9kg/m^2). All patients indicating a willingness to be approached about research were given the opportunity to participate in the study. Only women with polycystic ovaries were excluded from the study as it was anticipated they might represent an additional subgroup with a specific metabolic profile linked with this condition.

Ovarian stimulation and oocyte collection were performed as described (Dickerson, et al., 2010). There were no differences in the stimulation regimens administered to patients in this study, however the duration and starting dose was adjusted according to patient age, AMH and antral follicle count. The oocyte retrieval was scheduled once the second largest follicle had reached 18mm and all follicles above 15mm were drained. Oocytes were cultured at 37°C in 6% CO_2 , 5% O_2 , in Sage Quinn's Advantage (QA) Fertilisation Medium. Normally fertilised embryos were cultured until day 3 in QA Cleavage medium, and in QA Blastocyst medium until day 5 (all Sage QA products from Cooper Surgical, USA). Embryo transfer of one or two embryos was performed on day 3 or a single blastocyst on day 5, on the basis of the embryo

quality and surplus good quality blastocysts were cryopreserved for use in future treatment. Only then were patient consents checked and the remaining supernumerary developing embryos unsuitable for further clinical use donated to research, with full informed. Figure 1 depicts a summary of patients, oocytes and embryos included in each analysis. Observations were continued until day 9 or developmental arrest, to permit data capture from slower developing embryos which continued to show viability.

Oocyte assessments prior to ICSI and time-lapse development (observation and extended culture)

Oocyte diameters were measured during routine treatment and audited to assess differences in the quality of mature oocytes attained from normal weight and OW/OB women. Prior to ICSI two perpendicular measurements were taken of the ooplasm of 218 oocytes from 29 consecutive patients (see Figure 1A for details). As these measurements were taken prospectively, it was possible to track the onward developmental competence of the oocytes, based on their fertilisation, cleavage division to form embryos, development to form high scoring cleavage embryos, designated as having 6-8 cells on day 3 and a morphology score of grade 3 or above, and blastocyst formation on day 5.

Post transfer (68-116 hours post insemination) there was a total of 101 surplus embryos at various stages of continuing development which were placed into extended culture and observed using time-lapse technology (Primovision). Embryos were cultured in WOW dishes (Primovision, supplied by Vitrolife, Sweden), in culture conditions as described above. Recordings were made of specific developmental

timings/ events, using techniques described (Kirkegaard, et al., 2012). The time to reach 1) morula stage was defined as when all cells have fused, 2) unexpanded blastocyst; the first time a blastocyst is visible, 3) expanded blastocyst when the blastocoel expands 4) hatching; when the embryo escapes from the zona. The diameter of the blastocoel following collapse, recovery and hatching were also recorded.

Research embryo culture, assessment and metabolic assays

A second cohort of 29 consecutive patients presenting for IVF at the Hull IVF Unit donated a total of 150 embryos with full informed consent (See Figure 1C for details). Surplus embryos donated to research had their development stage recorded before being placed individually into 4µl drops of Earle's balanced salt solution, supplemented with 1mM glucose, 0.47mM pyruvate, 5mM Lactate, a physiological mixture of amino acids (Houghton, et al., 2002) (all obtained from Sigma-Aldrich Chemical, Poole, UK) and 0.5% (v/v) QA Serum Protein Substitute. Embryos were cultured under Sage Oil at 37°C in 5% CO₂ for 24 hours, alongside embryo-free control drops. Embryos were subsequently moved to fresh culture droplets and developmental observations made. Those embryos that had failed to form a blastocyst, but continued to undergo cell divisions/ organisation were classified as cleavage stage (cell number) or morula, whereas those that reached the blastocyst stage were classified according to their degree of expansion (unexpanded, expanded, hatched). An embryo that failed to develop after 48 hours culture was considered arrested. Observations were ended on day 9. After incubation the spent culture medium was immediately frozen at -80°C for later analysis.

Metabolic CORE profiles (Guerif et al., 2013) were determined by measuring the depletion and appearance of glucose, pyruvate, lactate and 18 amino acids, according to established techniques, that may be applied to individual oocytes and embryos:

(i) Glucose and pyruvate consumption and lactate production were measured using ultramicrofluorometric assays described by Leese and Barton (1984) and modified by Guerif et al., (2013). The assays are based on the enzymic phosphorylation of substrate and the subsequent consumption or generation of NADH or NADPH in coupled reactions which causes an increase in fluorescence which could be measured using a plate reader (Tecan Infinite M200) (excitation 340nm, fluorescence 459nm and above). All values are expressed as pmol embryo⁻¹ hour⁻¹.

(ii) A coupled colorimetric assay was used to measure triglycerides as described by Sturmey and Leese (2003). Samples were pooled in groups of 2 to 5 embryos at equivalent development stages for each patient.

(iii) Spent culture droplets were analysed for amino acids using reverse-phase high performance liquid chromatography (HPLC), as described by Houghton et al., (2002). Average sums of amino acid production and depletion, were expressed in pmol embryo⁻¹ hour⁻¹ for day 5 to 9 of culture. All data were normalised to a non-metabolisable internal standard. Results were recorded according to stage reached at the end of the period of culture

Blastocyst cell counts

Expanded blastocysts (n=44- see Figure 1B for details) were fixed on day 7 of development using the differential staining technique based on that described by

Thouas et al., (2001) for mouse and bovine blastocysts. Chromatin-specific dyes were used to determine ICM and TE counts.

Statistical analysis

The data were compared between normal and OW/OB women and correlated retrospectively to the study end points: (a) blastocyst development and (b) clinical pregnancy outcome of the sibling embryos from transferred sibling embryos (which had not been analysed). Analyses were performed using SPSS, power calculations were performed based on the Birket and Day method (Birkett and Day, 1994), and studies were designed to achieve 80% power, unless otherwise stated. Leven's test for normality was performed and ANOVA with Tukey Kramer as indicated.

Univariate regression analysis was used to compare continuous data with paired t-tests to compare grouped two sample data. ANOVA was used to assess intra- and inter-patient variability within the embryo cohort in combination with multiple linear regression analysis to determine the predictive accuracy of metabolic profile on blastocyst development rate. To account for patient-specific effects in the triglyceride data, where samples were necessarily pooled into groups, Generalised Estimating Equations were used to separately model the mean response and within-cluster associations to reduce the variance and increase the power. Principal component analysis was used to reduce the dimensionality of the individual 18 amino acid measurements and adjust for multiple testing.

Results

In each of the experimental groups there were no significant differences in patient demographics; female age, AMH, male age and mean cycle number. However, follicle and oocyte numbers were significantly lower in the OW/OB groups compared to normal weight women in the observational study. In addition, male BMI was found to be elevated in partners of OW/OB women and has thus been controlled for appropriately, as described in the statistical methods. Similarly, intra-patient variability, which was evident for each cohort of oocytes / embryos has been taken in to consideration.

We first compared oocyte diameter from overweight and obese women (BMI $>25\text{kg/m}^2$) to women with a BMI $<24.9\text{kg/m}^2$ (n=29 women, 218 oocytes in total) since oocyte diameter has been proposed as a marker of oocyte developmental competence (Wickramasinghe, et al., 1991). There were three key observations; women with a higher BMI had smaller oocytes ($p<0.01$, Figure 2A) more likely to be in the lower quartile range for diameter; smaller oocytes were less likely to complete cleavage after fertilisation (Fig 2B, $r=0.23$, $p<0.001$), and to form blastocysts ($r=0.28$, $p<0.001$). Intriguingly, despite higher rates of cleavage-stage arrest, embryos from oocytes from OW/OB women that were capable of reaching the morula stage did so 17 hours earlier than counterparts from women with a BMI <25 (Figure 2C $p<0.001$). The resulting blastocysts from women with a BMI $>25\text{kg/m}^2$ at equivalent time points, tended to be smaller ($p=0.07$) at the point of maximum expansion, and had significantly lower cell counts (Fig 3A). In a multivariate analysis of the expanded blastocyst data, only female BMI was shown to be a significant predictor of cell count (Fig 3B), independent of embryo diameter, female age, cause of infertility and male

BMI. Furthermore, at equivalent time points, embryos from overweight and OW/OB mothers had fewer trophectoderm cells ($p < 0.001$ (Fig 2B).

We next sought to discover whether the metabolic activity of 37 human blastocysts from 7 overweight/obese women differed from that of 113 blastocysts collected from 22 women who had a BMI < 24.9 . There were no other significant demographic differences between the groups including; age, cycle number and proportion IVF/ICSI cycles as determined by independent sample t-test (Figure 1C), however male partners of OW/OB had significantly higher BMIs than those paired with normal weight women. We found that embryos from women with a BMI in excess of 25 kg/m^2 consumed significantly less glucose than embryos from women of a healthy weight at equivalent stages of development ($p < 0.001$), whilst there were no significant changes in pyruvate uptake and lactate formation (Figure 4A). This pattern was consistent for each developmental stage. The reduced consumption of glucose occurred without a compensatory increase in pyruvate uptake, or of glycolytic activity as determined by lactate formation. In a multivariate analysis, developmental stage and female BMI were significant predictors of glucose uptake ($p < 0.05$) and independent of male BMI, age, cause of infertility embryo grade and day each stage was attained. We were fortunate to identify a single male sperm donor that had been used to fertilise oocytes from 6 women, all of whom had a different BMI. With the male factor was controlled in this way, we were able to confirm the results of the multivariate analysis, which suggested that differences in embryo glucose consumption were independent of male BMI (Figure 4B);

Given these significant differences in glucose consumption, we compared the amino acid metabolism of embryos from overweight and obese women to those with a BMI $< 24.9 \text{ kg/m}^2$. Increased overall amino acid turnover is indicative of poor embryo

quality in terms of implantation potential (Brison, et al., 2004) and DNA damage (Sturmey et al., 2009). Whilst we did not observe a significant difference in overall amino acid turnover, we did find that embryos from overweight women had striking differences in the consumption and release of individual amino acids compared to those from healthy weight women. Thus, the appearances in the culture medium of glutamate ($p<0.01$), aspartate ($p<0.001$), asparagine ($p<0.01$) and tryptophan ($p<0.05$) were elevated while the depletion of serine ($p<0.01$) and glutamine ($p<0.01$) were higher and that of isoleucine reduced in embryos from overweight group compared to normal weight women. When the analysis was restricted to developmental stage-matched blastocysts from the two BMI groupings the differences were less pronounced, however embryos from overweight women still depleted significantly more methionine than embryos from normal weight women ($p<0.05$ Figure 4C).

Finally, we asked whether embryos from overweight women contained more triglyceride than counterparts from women with a BMI $<24.9\text{kg/m}^2$. We observed that day 9 blastocysts from women with a BMI $>25\text{kg/m}^2$ contained significantly more triglyceride than comparable embryos from women with a BMI $<24.9\text{kg/m}^2$ (Fig 5A; $p<0.001$). Moreover embryos that arrested contained significantly more triglyceride than those that completed development (11.32 ng vs 6.7 ng; $p<0.001$, Fig 5B). This apparent retention of triglyceride and reduction in glucose consumption most likely originates from the period of oocyte development, since all embryos were cultured in equivalent conditions in vitro.

In terms of pregnancy outcome, the CORE glucose, lactate and pyruvate values given by sibling non-transferred embryos did not correlate with patient pregnancy outcome, however considerable intra-patient variability was observed. This variability was reduced when the analysis was limited to only developing sibling embryos alone, however no significant correlation with pregnancy was evident. Similarly, the mean turnover of amino acids for all embryos from women achieving pregnancies, despite appearing to be lower, was not significantly different to the non-pregnant group ($p=0.06$). When the analysis was limited to a comparison with developing blastocysts only, significant differences were observed in the production of asparagine ($p=0.02$) and glutamine ($p=0.04$), which were lower in the pregnant group, similarly the uptake of arginine ($p=0.03$) was lower. With regards to triglyceride content, this tended to be lower ($p=0.08$) in the sibling embryos from women achieving a pregnancy compared to those whose treatment was not successful.

Discussion

We report that embryos from overweight and obese women express a compromised developmental and metabolic phenotype. Specifically, oocytes from overweight and obese women are significantly smaller than those collected from women with a BMI considered to be in the healthy range. These smaller oocytes from overweight and obese women are less likely to reach the blastocyst stage, but those that do so, show accelerated preimplantation development and the subsequent blastocysts contain fewer cells, notably in the trophectoderm. These embryos also show significant metabolic abnormalities, with a diminished glucose consumption, altered profile of amino acid metabolism and strikingly, an increased endogenous triglyceride content. The data provide strong evidence for a direct link between maternal nutrition, the periconceptual environment, oocyte and preimplantation developmental competence and embryo metabolism, which could have long-term health implications for the offspring.

We found that oocytes collected from women with a BMI that exceeds 25 kg/m² are significantly smaller than comparable oocytes collected from women whose BMI is less than 25 kg/m²; a finding in agreement with that of Marquard, et al., (2011). The impact of this observation is not yet clear, but Lucifero, et al., (2004) reported that the diameter of mouse oocytes was correlated with the accumulation of transcripts encoding for *Dnmt3a*, *Dnmt3b* and *Dnmt3L*; enzymes which play a critical role in the establishment and maintenance of DNA methylation. Moreover, expression of one of these (DNMT3a) appears to be influenced by exposure of the oocyte to fatty acids (Van Hoeck, et al., 2011). This may indicate that the smaller oocytes from OW/OB women, exposed to elevated levels of fatty acids in the follicle, have dysregulated expression of enzymes with an essential role in regulating methylation and

epigenetic control in the resulting embryo Furthermore, fewer oocytes from overweight and obese women were competent to reach the blastocyst once fertilised; a finding that may contribute to the lower success rates of fertility treatment that have been reported in overweight and obese women (Bellver, et al., 2010, Chavarro, et al., 2012, Moragianni, et al., 2012, Shah, et al., 2011).

Although fewer embryos from overweight and obese women reached the blastocyst, those that did so developed at a faster rate; an unexpected finding. Specifically, embryos from overweight and obese women reached the morula stage of development on average 17 hours faster than comparable embryos from women of a healthy weight. This precocious pre-compaction development meant that blastocysts were formed earlier in overweight and obese women, although the duration of cavitation once the morula stage had been reached did not differ. The reasons behind this precocious development are unclear, particularly given the recent report by Bellver et al., (2013), who reported that embryos from overweight and obese patients had similar timings in cell division to embryos from women of normal weight. An important distinction between the work reported here and that of Bellver et al., (2013) relates the length of time that embryos were observed; Bellver et al., (2013) reported findings for 72 hours post fertilisation, although they did conceded that obesity may play an important role in the late stages of embryo development. We now report for the first time that differences in developmental timing between embryos from OW/OB patients only became apparent after 68 hours post insemination.

We were surprised to find that the resulting blastocysts had fewer cells, notably in the trophectoderm lineage. The presence of fewer cells in the TE, from which the cytotrophoblast and syncytiotrophoblast will form, implies that at the time of implantation, there are fewer chorionic progenitor cells, which we propose may have an impact on the size and invasive properties of the trophoblast and subsequent placenta. Disrupted cell allocation may have downstream effects on placental growth, which is likely to be important since both low and high placental weight at birth have been shown in epidemiological studies to predict the likelihood of developing coronary heart disease, hypertension, stroke and cancer in adulthood (Barker, et al., 1990, Eriksson, et al., 2011).

In broad terms, the data on consumption of glucose by single human blastocysts are consistent with those previously reported (Gardner, et al., 2011, Hardy, et al., 1989). However, blastocysts from overweight and obese patients consumed significantly less glucose than equivalent embryos from women with a BMI <24.9 kg/m². A diminished capacity to metabolise glucose may be profound since there appears to be an evolutionarily conserved metabolic phenotype such that cleavage-stage embryos preferentially utilise pyruvate, while there is a characteristic increase in glucose consumption (Smith and Sturmey, 2013) during blastocyst formation. A reduction of glucose consumption at the blastocyst stage suggests some degree of metabolic remodelling in the blastocysts derived from oocytes collected from overweight and obese women. There are a number of reports that link embryo metabolism to ongoing developmental potential and Gardner et al., (2011) have proposed that low glucose consumption at the blastocyst stage relates to reduced human embryo viability. Given that in the current study, all of the embryos were cultured in equivalent conditions, we conclude that the origins of the altered glucose

metabolism in human blastocysts from overweight women can be traced back to conditions in the ovary. In addition, we were fortunate in having a cohort of 6 patients who received donor semen from a single donor, allowing us in essence to confirm the results from our statistical model which suggest that embryo metabolism is independent of male BMI. We observed a significant negative correlation between mean glucose consumption of blastocysts and female BMI, when the male contribution was controlled for, further supporting the conclusion that the origin of the metabolic alterations observed in the current study can be linked to the environment within the ovary. However, there is good evidence that male obesity can also impact on fertility and embryo viability (Bakos, et al., 2011). The molecular mechanism by which intra-follicular conditions modify the oocyte and subsequent embryo is unclear, but we consider it highly significant that bovine oocytes exposed to fatty acids at concentrations found in human ovarian follicles, (Robker, et al., 2009, Valckx, et al., 2012) display reduced glucose consumption in the subsequent blastocysts (Van Hoeck et al 2011) as in our present study.

The blastocysts of overweight and obese women consumed and produced a number of amino acids in increased quantities, compared to counterparts from women of a BMI $<24.9 \text{ kg/m}^2$, further pointing to a degree of metabolic regulation. The increased appearance of aspartate and glutamate in embryos from OW/OB women might be indicative of a disrupted malate-aspartate shuttle (MAS), which plays a vital role in regulating glucose metabolism in mouse blastocysts (Mitchell, et al., 2009), and has a further function in regulating the REDOX status of the cytosol. It is also noteworthy that inadequate metabolism of amino acids leads to a delay in trophectoderm development through an mTOR-dependent pathway (Martin and Sutherland, 2001). Given that we observed a reduction in TE cells in the embryos from overweight and

obese patients, and reduced amino acid metabolism, it is tempting to speculate that there is some degree of disruption to the mTOR signalling in these blastocysts. In addition, embryos from overweight women consumed significantly more methionine which plays an important role in the metabolic regulation of nucleotide synthesis and methylation (Grillo and Colombatto, 2008); processes likely to be important up to the stage of blastocyst expansion which coincides with the end of DNA demethylation and loss of histone modifications and the onset of methylation (Feng, et al., 2010).

This is the first quantitative report of triglyceride in human blastocysts, the total content of which was significantly lower than that observed in the domestic species (Ferguson and Leese, 1999, Sturmey and Leese, 2003, Sturmey, et al., 2009). Total endogenous triglyceride concentrations were lower in embryos that successfully develop to the blastocyst stage and that blastocysts derived from oocytes of overweight and obese patients contained significantly elevated levels of endogenous triglyceride. It is unlikely that *de novo* synthesis of fatty acid occurs in the embryo, although this cannot be discounted; more likely that oocytes present in the lipid-rich follicles of overweight and obese women accumulate triglyceride from the surrounding environment as reported by Aardema et al., (2011) and Ferguson and Leese, (1999) for domestic species. This increased concentration of endogenous triglyceride is further evidence of metabolic remodelling in blastocysts derived from oocytes of overweight and obese women, and may explain the reduction in glucose consumption, since it is widely established in somatic cells and tissues that an increase in β -oxidation causes a reduction in glycolysis via elevated cytosolic citrate levels which inhibit phosphofructokinase (Hue and Taegtmeyer, 2009).

The data comparing metabolic parameters to the pregnancy outcome of the sibling transferred embryos highlights the differences in developmental potential apparent in a cohort of embryos; a potential weakness of using the woman as the 'experimental unit' as opposed to individual embryos. This assumes that the intra follicular conditions were comparable in the ovaries of a patient. However in a given patient, even in follicles of comparable size, the degree of vascularization, oxygenation and level of nutrients have been shown to vary at the time of ovum retrieval (reviewed by Van Blerkom et al 2000). The more subtle differences in metabolic regulation and developmental competence of individual embryos could be attributed to these differences and further studies are required on the origin of intra follicular influences.

Studies on the consequences of maternal obesity have largely focussed on clinical complications for the mother during pregnancy and on offspring health; short- and long-term. Due to the complexities in working with human embryos and scarcity of material, much research on the impact of obesity on early development has been carried out in experimental animals (Van Hoeck, et al., 2011, Vogt, et al., 2014).

Such data suggest that the early embryo is especially sensitive to nutritional and environmental challenges during the periconceptual period. Recent research efforts have begun to characterise the 're-programming' that occurs at this time, and the consequences for future development. We believe that the work presented here is the first to examine the impact of maternal overweight or obesity on the development and nutrition of human oocytes and preimplantation embryos and shows that maternal metabolic health acts via the ovary to alter the phenotype of the oocyte.

These alterations persist in the zygote and manifest, in our study as a disrupted metabolism at the blastocyst stage with the potential to compromise fetal and offspring health.

492 **Author roles:** CL, HJL and RGS conceived the study. CL and RGS performed the research
493 and analysed the data. CL, HJL and RGS wrote the manuscript. All authors had access to
494 data at all times.

495 **Acknowledgements:** The authors are grateful to staff and patients at the Hull IVF Unit for
496 their assistance. Moreover, the authors wish to thank Professors Tom P Fleming
497 (Southampton), Khalid M Naseem (HYMS), Stephen R Killick (Hull), Jo L Leroy (Antwerp) and
498 Sir Richard L Gardner (York) for commenting on the manuscript whilst in preparation

499 **Funding:** The study was funded by the Hull IVF Unit Charitable Trust and the Hull York
500 Medical School.

501

502 **References;**

- 503 Aardema H, Vos PL, Lolicato F, Roelen BA, Knijn HM, Vaandrager AB, Helms JB, Gadella BM.
 504 Oleic acid prevents detrimental effects of saturated fatty acids on bovine oocyte
 505 developmental competence. *Biology of reproduction* 2011;**85**: 62-69.
- 506 Bakos HW, Henshaw RC, Mitchell M, Lane M. Paternal body mass index is associated with
 507 decreased blastocyst development and reduced live birth rates following assisted
 508 reproductive technology. *Fertility and sterility* 2011;**95**: 1700-1704.
- 509 Balen AH, Anderson RA, Policy, Practice Committee of the BFS. Impact of obesity on female
 510 reproductive health: British Fertility Society, Policy and Practice Guidelines. *Human fertility*
 511 2007;**10**: 195-206.
- 512 Barker DJ, Bull AR, Osmond C, Simmonds SJ. Fetal and placental size and risk of hypertension
 513 in adult life. *Bmj* 1990;**301**: 259-262.
- 514 Bellver J, Ayllon Y, Ferrando M, Melo M, Goyri E, Pellicer A, Remohi J, Meseguer M. Female
 515 obesity impairs in vitro fertilization outcome without affecting embryo quality. *Fertility and*
 516 *sterility* 2010;**93**: 447-454.
- 517 Bellver J, Mifsud A, Grau N, Privitera L, Meseguer M. Similar morphokinetic patterns in
 518 embryos derived from obese and normoweight infertile women: a time-lapse study. *Hum*
 519 *Reprod* 2013;**28**: 794-800.
- 520 Birkett MA, Day SJ. Internal pilot studies for estimating sample size. *Statistics in medicine*
 521 1994;**13**: 2455-2463.
- 522 Boots C, Stephenson MD. Does obesity increase the risk of miscarriage in spontaneous
 523 conception: a systematic review. *Seminars in reproductive medicine* 2011;**29**: 507-513.
- 524 Brison DR, Houghton FD, Falconer D, Roberts SA, Hawkhead J, Humpherson PG, Lieberman
 525 BA, Leese HJ. Identification of viable embryos in IVF by non-invasive measurement of amino
 526 acid turnover. *Hum Reprod* 2004;**19**: 2319-2324.

- 527 Butcher L, Coates A, Martin KL, Rutherford AJ, Leese HJ. Metabolism of pyruvate by the early
528 human embryo. *Biology of reproduction* 1998;**58**: 1054-1056.
- 529 Chavarro JE, Ehrlich S, Colaci DS, Wright DL, Toth TL, Petrozza JC, Hauser R. Body mass index
530 and short-term weight change in relation to treatment outcomes in women undergoing
531 assisted reproduction. *Fertility and sterility* 2012;**98**: 109-116.
- 532 Connor KL, Vickers MH, Beltrand J, Meaney MJ, Sloboda DM. Nature, nurture or nutrition?
533 Impact of maternal nutrition on maternal care, offspring development and reproductive
534 function. *The Journal of physiology* 2012;**590**: 2167-2180.
- 535 Dickerson EH, Cho LW, Maguiness SD, Killick SL, Robinson J, Atkin SL. Insulin resistance and
536 free androgen index correlate with the outcome of controlled ovarian hyperstimulation in
537 non-PCOS women undergoing IVF. *Hum Reprod* 2010;**25**: 504-509.
- 538 Dunning KR, Cashman K, Russell DL, Thompson JG, Norman RJ, Robker RL. Beta-oxidation is
539 essential for mouse oocyte developmental competence and early embryo development.
540 *Biology of reproduction* 2010;**83**: 909-918.
- 541 Eriksson JG, Kajantie E, Thornburg KL, Osmond C, Barker DJ. Mother's body size and
542 placental size predict coronary heart disease in men. *European heart journal* 2011;**32**: 2297-
543 2303.
- 544 Feng S, Jacobsen SE, Reik W. Epigenetic reprogramming in plant and animal development.
545 *Science* 2010;**330**: 622-627.
- 546 Ferguson EM, Leese HJ. Triglyceride content of bovine oocytes and early embryos. *Journal of*
547 *reproduction and fertility* 1999;**116**: 373-378.
- 548 Ferguson EM, Leese HJ. A potential role for triglyceride as an energy source during bovine
549 oocyte maturation and early embryo development. *Molecular reproduction and*
550 *development* 2006;**73**: 1195-1201.

551 Gardner DK, Wale PL, Collins R, Lane M. Glucose consumption of single post-compaction
 552 human embryos is predictive of embryo sex and live birth outcome. *Hum Reprod* 2011;**26**:
 553 1981-1986.

554 Gluckman PD, Hanson MA. Living with the past: evolution, development, and patterns of
 555 disease. *Science* 2004;**305**: 1733-1736.

556 Gott AL, Hardy K, Winston RM, Leese HJ. Non-invasive measurement of pyruvate and
 557 glucose uptake and lactate production by single human preimplantation embryos. *Hum*
 558 *Reprod* 1990;**5**: 104-108.

559 Grillo MA, Colombatto S. S-adenosylmethionine and its products. *Amino acids* 2008;**34**: 187-
 560 193.

561 Guerif F, McKeegan P, Leese HJ, Sturmey RG. A Simple Approach for CONsumption and
 562 RElease (CORE) Analysis of Metabolic Activity in Single Mammalian Embryos. *PloS one*
 563 2013;**8**: e67834.

564 Hanson M, Gluckman P. Developmental origins of noncommunicable disease: population
 565 and public health implications. *The American journal of clinical nutrition* 2011;**94**: 1754S-
 566 1758S.

567 Hardy K, Hooper MA, Handyside AH, Rutherford AJ, Winston RM, Leese HJ. Non-invasive
 568 measurement of glucose and pyruvate uptake by individual human oocytes and
 569 preimplantation embryos. *Hum Reprod* 1989;**4**: 188-191.

570 Houghton FD, Hawkhead JA, Humpherson PG, Hogg JE, Balen AH, Rutherford AJ, Leese HJ.
 571 Non-invasive amino acid turnover predicts human embryo developmental capacity. *Hum*
 572 *Reprod* 2002;**17**: 999-1005.

573 Hue L, Taegtmeyer H. The Randle cycle revisited: a new head for an old hat. *American*
 574 *journal of physiology Endocrinology and metabolism* 2009;**297**: E578-591.

575 Kirkegaard K, Agerholm IE, Ingerslev HJ. Time-lapse monitoring as a tool for clinical embryo
 576 assessment. *Hum Reprod* 2012;**27**: 1277-1285.

577 Kono T, Obata Y, Yoshimzu T, Nakahara T, Carroll J. Epigenetic modifications during oocyte
 578 growth correlates with extended parthenogenetic development in the mouse. *Nature*
 579 *genetics* 1996;**13**: 91-94.

580 Lawlor DA, Relton C, Sattar N, Nelson SM. Maternal adiposity--a determinant of perinatal
 581 and offspring outcomes? *Nature reviews Endocrinology* 2012;**8**: 679-688.

582 Leese HJ, Barton AM. Pyruvate and glucose uptake by mouse ova and preimplantation
 583 embryos. *Journal of reproduction and fertility* 1984;**72**: 9-13.

584 Lucifero D, Mann MR, Bartolomei MS, Trasler JM. Gene-specific timing and epigenetic
 585 memory in oocyte imprinting. *Hum Mol Genet* 2004;**13**: 839-849.

586 Machtinger R, Combelles CM, Missmer SA, Correia KF, Fox JH, Racowsky C. The association
 587 between severe obesity and characteristics of failed fertilized oocytes. *Hum Reprod* 2012;**27**:
 588 3198-3207.

589 Marquard KL, Stephens SM, Jungheim ES, Ratts VS, Odem RR, Lanzendorf S, Moley KH.
 590 Polycystic ovary syndrome and maternal obesity affect oocyte size in in vitro
 591 fertilization/intracytoplasmic sperm injection cycles. *Fertility and sterility* 2011;**95**: 2146-
 592 2149, 2149 e2141.

593 Martin KL, Hardy K, Winston RM, Leese HJ. Activity of enzymes of energy metabolism in
 594 single human preimplantation embryos. *Journal of reproduction and fertility* 1993;**99**: 259-
 595 266.

596 Martin PM, Sutherland AE. Exogenous amino acids regulate trophectoderm differentiation in
 597 the mouse blastocyst through an mTOR-dependent pathway. *Developmental biology*
 598 2001;**240**: 182-193.

599 Mitchell M, Cashman KS, Gardner DK, Thompson JG, Lane M. Disruption of mitochondrial
 600 malate-aspartate shuttle activity in mouse blastocysts impairs viability and fetal growth.
 601 *Biology of reproduction* 2009;**80**: 295-301.

602 Moragianni VA, Jones SM, Ryley DA. The effect of body mass index on the outcomes of first
 603 assisted reproductive technology cycles. *Fertility and sterility* 2012;**98**: 102-108.

604 Reynolds RM, Allan KM, Raja EA, Bhattacharya S, McNeill G, Hannaford PC, Sarwar N, Lee AJ,
 605 Bhattacharya S, Norman JE. Maternal obesity during pregnancy and premature mortality
 606 from cardiovascular event in adult offspring: follow-up of 1 323 275 person years. *Bmj*
 607 2013;**347**: f4539.

608 Robker RL, Akison LK, Bennett BD, Thrupp PN, Chura LR, Russell DL, Lane M, Norman RJ.
 609 Obese women exhibit differences in ovarian metabolites, hormones, and gene expression
 610 compared with moderate-weight women. *The Journal of clinical endocrinology and*
 611 *metabolism* 2009;**94**: 1533-1540.

612 Rogers IS, Ness AR, Steer CD, Wells JC, Emmett PM, Reilly JR, Tobias J, Smith GD.
 613 Associations of size at birth and dual-energy X-ray absorptiometry measures of lean and fat
 614 mass at 9 to 10 y of age. *The American journal of clinical nutrition* 2006;**84**: 739-747.

615 Shah DK, Missmer SA, Berry KF, Racowsky C, Ginsburg ES. Effect of obesity on oocyte and
 616 embryo quality in women undergoing in vitro fertilization. *Obstetrics and gynecology*
 617 2011;**118**: 63-70.

618 Smith DG, Sturmey RG. Parallels between embryo and cancer cell metabolism. *Biochemical*
 619 *Society transactions* 2013;**41**: 664-669.

620 Sturmey RG, Hawkhead JA, Barker EA, Leese HJ. DNA damage and metabolic activity in the
 621 preimplantation embryo. *Hum Reprod* 2009;**24**: 81-91.

622 Sturmey RG, Leese HJ. Energy metabolism in pig oocytes and early embryos. *Reproduction*
 623 2003;**126**: 197-204.

624 Sturmey RG, Reis A, Leese HJ, McEvoy TG. Role of fatty acids in energy provision during
 625 oocyte maturation and early embryo development. *Reproduction in domestic animals =*
 626 *Zuchthygiene* 2009;**44** Suppl 3: 50-58.

627 Thouas GA, Korfiatis NA, French AJ, Jones GM, Trounson AO. Simplified technique for
 628 differential staining of inner cell mass and trophectoderm cells of mouse and bovine
 629 blastocysts. *Reproductive biomedicine online* 2001;**3**: 25-29.

630 Valckx SD, De Pauw I, De Neubourg D, Inion I, Berth M, Fransen E, Bols PE, Leroy JL. BMI-
 631 related metabolic composition of the follicular fluid of women undergoing assisted
 632 reproductive treatment and the consequences for oocyte and embryo quality. *Hum Reprod*
 633 2012;**27**: 3531-3539.

634 Van Blerkom J. Intrafollicular influences on human oocyte developmental competence:
 635 perifollicular vascularity, oocyte metabolism and mitochondrial function. *Hum Reprod*
 636 2000;**15**(Suppl2): 173-188.

637 Van Hoeck V, Sturmey RG, Bermejo-Alvarez P, Rizos D, Gutierrez-Adan A, Leese HJ, Bols PE,
 638 Leroy JL. Elevated non-esterified fatty acid concentrations during bovine oocyte maturation
 639 compromise early embryo physiology. *PloS one* 2011;**6**: e23183.

640 Vogt MC, Paeger L, Hess S, Steculorum SM, Awazawa M, Hampel B, Neupert S, Nicholls HT,
 641 Mauer J, Hausen AC *et al.* Neonatal insulin action impairs hypothalamic neurocircuit
 642 formation in response to maternal high-fat feeding. *Cell* 2014;**156**: 495-509.

643 Walker CL, Ho SM. Developmental reprogramming of cancer susceptibility. *Nature reviews*
 644 *Cancer* 2012;**12**: 479-486.

645 Wickramasinghe D, Ebert KM, Albertini DF. Meiotic competence acquisition is associated
 646 with the appearance of M-phase characteristics in growing mouse oocytes. *Developmental*
 647 *biology* 1991;**143**: 162-172.

648


649 **Figure Legends**

Figure 1 Schematic diagram of the study groups A-D

Figure 1 Schematic diagram of the study groups A-D, indicating patient numbers and demographics for each of the groupings (values are \pm standard error). There were no difference in patient age and cycle number, significant differences in follicle and oocyte numbers in the observational study and male BMI in the CORE research grouping have been appropriately controlled for in the multivariate statistical analyses. Shaded boxes indicate oocytes and embryos included within the analysis.





Figure 2 Developmental differences exist between oocytes generated from normal and Overweight & Obese (OW/OB) women. **2A)** Oocyte diameter is inversely correlated to female BMI. The data show mean (\pm SEM) oocyte diameters ($n=218$), recorded from 29 women ($R^2=-0.45$; $p=0.001$). **2B)** The smallest oocytes, were significantly less likely to cleave ($p<0.001$) and more likely to have originated from women with a higher BMI ($p<0.001$; 29 patients, $n=155$ embryos). **2C)** The time elapsed post insemination for morula stage to be reached is shorter in embryos from OW/OB women compared to normal weight women ($p<0.001$, 25 patients, $n= 101$ supernumerary embryos taken for extended culture

666 observation). As a consequence, post compaction stages of development arise earlier in
 667 embryos from OW/OB women, although the duration taken to complete blastocyst formation
 668 from the morula does not differ between OW/OB and normal weight women, suggesting
 669 precocious cleavage stage development. Note: discrepancies in numbers of embryos reflect
 670 exclusions from subsequent analysis due to fail-to fertilise oocytes (63 oocytes) and embryos
 671 transferred or cryopreserved as part of clinical treatment (54 embryos) – See Fig 1A for
 672 details.



673


674 **Figure 3;** Total blastocyst cell counts, inner cell mass and trophectoderm cell counts for
 675 embryos that had been donated into research and had reached expanded blastocysts by day
 676 7 of development (n= 44; see Fig 1B for details). **3A)** Shows that total, ICM and TE cell
 677 counts were significantly lower in blastocysts from OW/OB compared to normal weight
 678 women (p=0.01; mean values displayed). **3B)** Shows the total, ICM and TE blastocyst cell
 679 counts, according to measures of total blastocyst diameter (μm) and ICM diameter (μm).

680 Blastocyst diameter shows a weak inverse relationship with female BMI ($P=0.07$). In a
 681 multivariate analysis diameter is not an independent predictor of cell count, whereas BMI is.
 682 The ICM count is predicted by female BMI and there is a trend for increased cell count with
 683 ICM diameter ($p=0.08$). The diameter of the ICM does not correlate with total cell count or
 684 total blastocyst diameter.

685

686 **Figure 4** Significant differences in the metabolism of embryos generated from normal and
 687 Overweight & Obese (OW/OB) women that had been donated into research (see Fig 1C for
 688 details). **4A)** Embryos from women classified as OW/OB consume significantly less glucose
 689 than normal weight counterparts ($p<0.001$ 37 embryos from 7 OW/OB women and 113
 690 embryos from 22 normal weight women. Error bars represent 95% CI). **4B)** The glucose
 691 consumption of blastocysts is inversely correlated to female BMI ($R^2=-0.61$; $p=0.001$) and
 692 relates to maternal BMI with little paternal influence. The oocytes in this figure were all
 693 fertilised by the same sperm donor, yet reduced glucose consumption was apparent in
 694 embryos from OW/OB women. (12 embryos from 3 women of a normal BMI and 13 embryos
 695 from 3 OW/OB women; See Fig 1D for details. Data are expressed as mean \pm SEM) **4C)**
 696 Amino acid depletion (negative values) and appearance (positive values) by blastocysts of
 697 equivalent stage for OW/OB ($n=20$ blastocysts from 37 embryos total) and normal weight
 698 women ($n=27$ blastocysts from 113 embryos; see Fig 1C for details). There are no significant
 699 differences in the sum of uptake and production, however blastocysts from OW/OB women
 700 depleted significantly more methionine than embryos from women of healthy weight
 701 ($p=0.037$). Error bars represent 95% CI.

Fig 4



702

703 **Figure 5:** Triglyceride content of human embryos is influenced by maternal BMI. **5A)**

704 Embryos that had been donated into research (see Fig 1C for details) derived from oocytes

705 collected from OW/OB women contain significantly more triglyceride than those from healthy

706 weight women ($t=4.11$, $**p<0.001$). **5B)** Embryos that arrest prior to the blastocyst stage707 ($n=88$) contain significantly more triglyceride than those capable of forming blastocysts ($n=52$;708 $t=6.79$, $p<0.001$), error bars represent standard error. Note, 10 embryos were unsuitable for

709 analysis. This finding was consistent in both the normal weight and OW/OB women. Data are

710 expressed as mean TG content \pm SEM.